Indo MIM Shares Soar 10%, Marking 82% Surge from Issue Price: Time for Investors to Cash In?

Indo MIM has emerged as a noteworthy performer in the equity market following its recent IPO, with shares soaring over 10% to Rs 862 on the BSE, reflecting a cumulative gain of 82% from the issue price since its listing on July 30. Initially, the stock debuted at a robust 44.95% premium to the IPO price, opening at Rs 703 on the BSE and Rs 700 on the NSE against an issue price of Rs 485. The offering, which was available from July 23 to July 27, garnered exceptional interest, culminating in a subscription ratio of 98.47 times, underscoring strong demand from Qualified Institutional Buyers (QIBs) and high-net-worth individuals.

Shivani Nyati, Head of Wealth at Swastika Investmart Ltd., highlighted that the remarkable listing performance of Indo MIM can be attributed to its prominent position in the global Metal Injection Molding (MIM) market. However, she cautioned that investors might consider profit booking in the near term, given the substantial price jump post-listing. This strategic advice aligns with typical market behavior observed after an initial surge in stock prices, suggesting a prudent approach for current shareholders.

Financially, Indo MIM exhibited robust performance in FY26, reporting a total income growth of 28.1% year-on-year to Rs 4,320.70 crore, up from Rs 3,373.97 crore in FY25. Additionally, the profit after tax (PAT) increased by 25.9% to Rs 533.54 crore, compared to Rs 423.73 crore in the previous fiscal year. This impressive financial trajectory reinforces the company’s operational efficacy and market positioning as one of the leading manufacturers of precision engineering components.

Established in 1996, Indo MIM has expanded its core offerings in MIM technology by incorporating advanced manufacturing processes such as investment casting, precision machining, ceramic injection molding, and 3D metal printing. With a diverse product portfolio serving industries ranging from automotive to aerospace and medical devices, the company manufactured over 6,400 distinct products in FY26. This diversification not only amplifies its market reach but also enhances its resilience against sector-specific downturns, positioning it favorably for sustained growth.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova team.)